IL10 and inflammatory bowel disease: Combined with the fact that AHR activators can suppress IL-6 expression by bone marrow stromal cells, and ameliorate DSS-induced acute colitis by increasing IL-10 and suppressing IFN-γ expression [46,47], correcting impaired microbiota functions to improve AHR ligands production is a promising strategy in IBD.